Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss drug Wegovy. | Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy,

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar deal with Hims & Hers Health (NYSE:HIMS) that gave the telehealth firm direct access to the company's blockbuster GLP-1 therapy.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their prescription filled through CenterWell Pharmacy, now associated with Novo Nordisk and WeightWatchers.